 At the start of March, BridgeBio Pharma Inc NASDAQ: BBIO won approval for its first drug, fosdenopterin, for sporadic cases of molybdenum cofactor deficiency type A. In the middle of March, it announced positive proof-of-concept data for encaleret for Autosomal Dominant Hypocalcemia Type 1 ADH1. 